Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Patent Reform Gets Renewed Interest From GOP As Alternative To Price Negotiation

Executive Summary

A Republican congressman and witness discuss shortened IP protections while criticizing Nancy Pelosi's drug price negotiation plan.

You may also be interested in...



Outgoing BIO CEO Focuses On Out-Of-Pocket Costs As Solution To Drug Pricing Woes

In interview with the Pink Sheet, Jim Greenwood also worries about President Trump promoting drug pricing policies that could hinder innovation.

AAM Launches US Ad Campaign

The seven-figure DTC ad campaign is an unusual tactic for the generics industry, which typically uses other channels for its advocacy.

Generics Trade Association Takes Generic Access Concerns Directly To Patients

The seven-figure DTC ad campaign is an unusual tactic for the generics industry, which typically uses other channels for its advocacy.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel